Lower Extremity Muscle Strengthening Program in Myotonic Dystrophy Type 1 from Groupe de recherche interdisciplinaire sur les maladies neuromusculaires
Myotonic dystrophy (DM1) is a rare hereditary disease that presents with several clinical manifestations including muscle weakness, apathy and fatigue. Currently it is only possible to treat the symptoms of the disease and not the disease itself. To help address the symptoms experienced by people with DM1, the Groupe de recherche interdisciplinaire sur les maladies neuromusculaires (GRIMN) developed a muscle strengthening program which has led to significant gains in muscle strength, functional capacity, decreased apathy and reduced fatigue (1,2,3).
GRIMN recently created a video aimed at health professionals that provides an in-depth explanation of the DM1 training parameters used in their studies. This video presents a strength training program designed for individuals with DM1
This resource is primarily intended for healthcare professionals working with the DM1 population, particularly physiotherapists who are most directly involved in implementing strength training interventions. It is also relevant for individuals living with DM1, who are encouraged to present it to their healthcare providers.
The video is available in both English and French on the GRIMN web page.
- Gallais, M. P. Roussel, L. Laberge, L. J. Hebert, E. Duchesne, Impact of a 12-week Strength Training Program on Fatigue, Daytime Sleepiness, and Apathy in Men with Myotonic Dystrophy Type 1. J Neuromuscul Dis 9, 629-639 (2022).
- Girard-Cote et al., Resistance training in women with myotonic dystrophy type 1: a multisystemic therapeutic avenue. Neuromuscul Disord 40, 38-51 (2024).
- P. Roussel, L. J. Hebert, E. Duchesne, Strength-training effectively alleviates skeletal muscle impairments in myotonic dystrophy type 1. Neuromuscul Disord 30, 283-293 (2020).
Read next...
A Milestone in Neuromuscular Care: AGAMREE® (vamorolone) Approved as the First Treatment for Duchenne Muscular Dystrophy in Canada
Health Canada has approved AGAMREE® (vamorolone), the first-ever treatment for Duchenne Muscular Dystrophy (DMD) in Canada. Patient Support Program opens for enrollment on October 10, 2025.
New Best Practice Recommendations for SBMA Care in Canada
Congratulations to Dr. Kerri Schellenberg, the team of Canadian experts, NMD4C Steering Committee members and Investigators, on publishing the first Canadian SBMA care guidelines!
Advancing Neuromuscular Research and Care: Highlights from the 2025 NMD4C Annual Meeting
On September 11, NMD4C hosted its 2025 Annual Meeting in Ottawa, bringing together clinicians, researchers, trainees, and partners for a full day of collaboration, strategic dialogue, and community-building.
NMD4C Hosts Inaugural Clinical Summer School to Empower Canada’s Future Neuromuscular Leaders
On September 10–11, NMD4C hosted its inaugural Clinical Summer School in Ottawa, bringing together 19 neuromuscular clinical fellows from across Canada for two days of hands-on training, mentorship, and networking. Led by national experts and co-chaired by Drs. Gordon Jewitt and Marianne Nury, the program complemented NMD4C’s accredited lecture series and fostered peer connection through dedicated community-building sessions.
2026 Neuromuscular Postdoctoral Research Fellowships Funding Competition is Now Open!
Apply Or Share this opportunity with the trainees in your network — Deadline: October 14, 2025. Hosted by Neuromuscular Disease Network for Canada (NMD4C) and Muscular Dystrophy Canada (MDC)
Announcing the 2026 Neuromuscular Clinical Fellowship Award Recipients
We are excited to share that the 2026 Neuromuscular Clinical Fellowship Awards have been awarded! These fellowships strengthen clinical training in neuromuscular medicine and help prepare the next generation of specialists who will advance neuromuscular care across Canada.